|By PR Newswire||
|July 31, 2014 05:39 PM EDT||
SAN DIEGO, July 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.
"Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Amar's family and friends," said Henry Ji, Ph.D., Sorrento's President and Chief Executive Officer.
Mr. Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where he served as SVP and Chief Business Officer since December 2010. Previously, Mr. Singh served as: Chief Operating Officer of Spectrum Pharmaceuticals, where he led the commercial and business development teams; VP and Chief Commercial Officer at Novacea responsible for securing partnerships; and Chief Commercial Officer at Abraxis where he led the launch of Abraxane®. Prior to Abraxis, Mr. Singh held multiple commercial leadership positions in the oncology franchise at Hoffman-La Roche for over 10 years. Mr. Singh holds an M.B.A. from the Stern School of Business at New York University and a B.A. from the University of North Carolina at Chapel Hill.
About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bispecific therapeutic antibodies, and ADCs.
More information is available at www.sorrentotherapeutics.com.
SOURCE Sorrento Therapeutics, Inc.
Sep. 28, 2016 08:30 PM EDT Reads: 403
If you’re responsible for an application that depends on the data or functionality of various IoT endpoints – either sensors or devices – your brand reputation depends on the security, reliability, and compliance of its many integrated parts. If your application fails to deliver the expected business results, your customers and partners won't care if that failure stems from the code you developed or from a component that you integrated. What can you do to ensure that the endpoints work as expect...
Sep. 28, 2016 08:30 PM EDT Reads: 1,704
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Sep. 28, 2016 08:15 PM EDT Reads: 307
Sep. 28, 2016 07:00 PM EDT Reads: 1,624
Sep. 28, 2016 06:45 PM EDT Reads: 4,150
Sep. 28, 2016 06:30 PM EDT Reads: 3,106
Sep. 28, 2016 06:15 PM EDT Reads: 279
Sep. 28, 2016 06:00 PM EDT Reads: 1,770
Sep. 28, 2016 05:15 PM EDT Reads: 239
Sep. 28, 2016 05:15 PM EDT Reads: 245
Sep. 28, 2016 05:00 PM EDT Reads: 1,724
Sep. 28, 2016 04:30 PM EDT Reads: 2,812
Sep. 28, 2016 04:15 PM EDT Reads: 1,496
Sep. 28, 2016 04:15 PM EDT Reads: 2,437
Sep. 28, 2016 04:15 PM EDT Reads: 1,873